Qpex Biopharma, Inc.
Qpex Biopharma Inc., a Shionogi Group Company, is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel anti-infective therapies. Their focus is on addressing antimicrobial resistance through innovative drug discovery, including their lead program based on xeruborbactam, a beta-lactamase inhibitor. The company leverages decades of expertise in drug resistance mechanisms and collaborates with government, academia, and industry to meet unmet medical needs in infectious diseases.
Industries
Nr. of Employees
small (1-50)
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. 10075 Barnes Canyon Road Suite 510 San Diego, CA 92121
Patents
Products
Clinical-stage investigational boronate beta-lactamase inhibitor (IV and oral prodrug development)
A clinical-stage boronate-class beta-lactamase inhibitor developed to inhibit a broad spectrum of serine and metallo-beta-lactamases and restore activity of beta-lactam antibiotics in resistant Gram-negative pathogens; being advanced in intravenous combinations and an oral prodrug formulation.
Synthetic lipopeptide antibiotic candidate targeting multidrug-resistant Gram-negative pathogens
A synthetic lipopeptide antibiotic program developed to target multidrug-resistant Gram-negative bacteria; data published in a peer-reviewed journal and advanced through preclinical and early clinical evaluation.
Clinical-stage investigational boronate beta-lactamase inhibitor (IV and oral prodrug development)
A clinical-stage boronate-class beta-lactamase inhibitor developed to inhibit a broad spectrum of serine and metallo-beta-lactamases and restore activity of beta-lactam antibiotics in resistant Gram-negative pathogens; being advanced in intravenous combinations and an oral prodrug formulation.
Synthetic lipopeptide antibiotic candidate targeting multidrug-resistant Gram-negative pathogens
A synthetic lipopeptide antibiotic program developed to target multidrug-resistant Gram-negative bacteria; data published in a peer-reviewed journal and advanced through preclinical and early clinical evaluation.
Services
Strategic partnerships with government, academia and industry to advance anti-infective discovery and development programs.
Strategic partnerships with government, academia and industry to advance anti-infective discovery and development programs.
Expertise Areas
- Anti-infective drug discovery
- Beta-lactamase inhibitor development
- Microbiology and resistance mechanism characterization
- Translational pharmacology (PK/PD)
Key Technologies
- Boron-based medicinal chemistry
- X-ray co-crystallography / structural biology
- Enzyme inhibition assays
- In vitro antimicrobial susceptibility testing (MIC panels)